AU2005314810B2 - Method for reduction, stabilization and prevention of rupture of lipid rich plaque - Google Patents

Method for reduction, stabilization and prevention of rupture of lipid rich plaque Download PDF

Info

Publication number
AU2005314810B2
AU2005314810B2 AU2005314810A AU2005314810A AU2005314810B2 AU 2005314810 B2 AU2005314810 B2 AU 2005314810B2 AU 2005314810 A AU2005314810 A AU 2005314810A AU 2005314810 A AU2005314810 A AU 2005314810A AU 2005314810 B2 AU2005314810 B2 AU 2005314810B2
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
pitavastatin
hydrate
effective amount
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005314810A
Other languages
English (en)
Other versions
AU2005314810A1 (en
Inventor
Hideyuki Kobayashi
Kimiyuki Shibuya
Yasunobu Yoshinaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Publication of AU2005314810A1 publication Critical patent/AU2005314810A1/en
Application granted granted Critical
Publication of AU2005314810B2 publication Critical patent/AU2005314810B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2005314810A 2004-12-10 2005-12-09 Method for reduction, stabilization and prevention of rupture of lipid rich plaque Ceased AU2005314810B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63453204P 2004-12-10 2004-12-10
US60/634,532 2004-12-10
PCT/JP2005/023088 WO2006064889A1 (en) 2004-12-10 2005-12-09 Method for reduction, stabilization and prevention of rupture of lipid rich plaque

Publications (2)

Publication Number Publication Date
AU2005314810A1 AU2005314810A1 (en) 2006-06-22
AU2005314810B2 true AU2005314810B2 (en) 2010-08-26

Family

ID=36587943

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005314810A Ceased AU2005314810B2 (en) 2004-12-10 2005-12-09 Method for reduction, stabilization and prevention of rupture of lipid rich plaque

Country Status (11)

Country Link
US (2) US20090275595A1 (enExample)
EP (1) EP1827440A4 (enExample)
JP (1) JP2008522955A (enExample)
KR (1) KR100895031B1 (enExample)
CN (1) CN101068548B (enExample)
AU (1) AU2005314810B2 (enExample)
CA (1) CA2590224C (enExample)
NZ (1) NZ554924A (enExample)
RU (1) RU2351337C1 (enExample)
TW (1) TW200619204A (enExample)
WO (1) WO2006064889A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100438872C (zh) * 2003-08-29 2008-12-03 兴和株式会社 2-[4-[2-(苯并咪唑-2-基-硫代)乙基]哌嗪-1-基]-n-[2,4-二(甲基硫代)-6-甲基-3-吡啶基]乙酰胺的制药用途
US8048083B2 (en) * 2004-11-05 2011-11-01 Dfine, Inc. Bone treatment systems and methods
WO2011081118A1 (ja) * 2009-12-29 2011-07-07 興和株式会社 経口投与用医薬組成物
JPWO2011081117A1 (ja) * 2009-12-29 2013-05-09 興和株式会社 経口投与用固形医薬組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01279866A (ja) * 1987-08-20 1989-11-10 Nissan Chem Ind Ltd キノリン系メバロノラクトン類
WO1998054153A1 (en) * 1997-05-26 1998-12-03 Kowa Company, Ltd. Novel cyclic diamine compounds and medicine containing the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
SK284142B6 (sk) * 1995-11-02 2004-10-05 Warner-Lambert Company Farmaceutická kompozícia na reguláciu koncentrácie lipidov, stabilizáciu aterosklerotických lézií a na prevenciu pretrhnutia aterosklerotického plaku
US6969711B2 (en) * 1997-05-26 2005-11-29 Kowa Company, Ltd. Cyclic diamine compounds and medicine containing the same
RU2235483C2 (ru) * 1998-11-25 2004-09-10 Нутри Фарма Аса Композиция, фармацевтический препарат и способ для профилактики и/или лечения и/или ослабления сердечно-сосудистых заболеваний
WO2001022962A1 (en) * 1999-09-30 2001-04-05 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
IL153633A0 (en) * 2000-07-13 2003-07-06 Takeda Chemical Insustries Ltd Lipid-rich plaque inhibitors
HUP0301728A3 (en) * 2000-09-01 2004-05-28 Sankyo Co Hmg-coa reductase inhibiting pharmaceutical compositions and their use
US20060165605A1 (en) * 2001-12-28 2006-07-27 Ye-Mon Chen Process to regenerate fcc spent catalyst
MY140618A (en) * 2003-02-28 2009-12-31 Kowa Co Method for preparing acid addition salts of polyacidic basic compounds
US20060046996A1 (en) * 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01279866A (ja) * 1987-08-20 1989-11-10 Nissan Chem Ind Ltd キノリン系メバロノラクトン類
WO1998054153A1 (en) * 1997-05-26 1998-12-03 Kowa Company, Ltd. Novel cyclic diamine compounds and medicine containing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Llaverias et al. Eur. J. Pharmacol. (2002) vol. 451, no. 1, pages 11-17 *

Also Published As

Publication number Publication date
CN101068548B (zh) 2010-12-08
US20090275595A1 (en) 2009-11-05
RU2351337C1 (ru) 2009-04-10
EP1827440A4 (en) 2010-12-08
HK1111356A1 (en) 2008-08-08
TW200619204A (en) 2006-06-16
US20110207742A1 (en) 2011-08-25
CA2590224C (en) 2011-12-20
RU2007125976A (ru) 2009-01-20
KR100895031B1 (ko) 2009-04-24
NZ554924A (en) 2010-09-30
CN101068548A (zh) 2007-11-07
KR20070085508A (ko) 2007-08-27
AU2005314810A1 (en) 2006-06-22
EP1827440A1 (en) 2007-09-05
JP2008522955A (ja) 2008-07-03
WO2006064889A1 (en) 2006-06-22
CA2590224A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
US5674893A (en) Method for preventing reducing or risk of onset of cerebrovascular events employing an HMG CoA reductase inhibitor
ES2286995T3 (es) Uso de inhibidores de 3-hidroxi-3-metilglutaril coenzima a reductasa para la fabricacion de un medicamento para el tratamiento de neuropatia diabetica.
US20070105894A1 (en) Combination of at least two compounds selected from an AT1-receptorantagonist or an ACE inhibitor or a HMG-Co-A reductase inhibitor
CZ286832B6 (en) Compound pharmaceutical preparation for prevention and treatment of arteriosclerosis or xanthoma
US20110207742A1 (en) Method for reduction, stabilization and prevention of rupture of lipid rich plaque
TWI286935B (en) Use of a pyrazole derivative for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and-or to obesity
EP2787993B1 (en) TREATMENT OF ARTERIAL WALL BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
CN100438872C (zh) 2-[4-[2-(苯并咪唑-2-基-硫代)乙基]哌嗪-1-基]-n-[2,4-二(甲基硫代)-6-甲基-3-吡啶基]乙酰胺的制药用途
CN1330309C (zh) 用于预防或治疗由eNOS表达而引起的疾病的药物
CA2548790A1 (en) Medicinal compositions and combinations
WO2002030425A1 (en) Preventives and remedies for complications of diabetes
Kurata et al. Cerivastatin induces carotid artery plaque stabilization independently of cholesterol lowering in patients with hypercholesterolaemia
JP4892477B2 (ja) 新規なトリグリセリド低下剤
JP2007513991A (ja) メタボリック症候群の処置のためのスタチンの使用
HK1111356B (en) Method for reduction, stabilization and prevention of rupture of lipid rich plaque
US7750033B2 (en) Preventive and remedy for collagen or elastin metabolic disorder
US20050182036A1 (en) Medicinal composition containing an HMG-CoA reductase inhibitor
WO2006011495A1 (ja) 高コレステロール血症及び／又は高トリグリセリド血症治療剤
US20100041716A1 (en) Nitroxides for use in treating or preventing hypercholesterolemia
CN101415425B (zh) 甘油三酯降低剂和高胰岛素血症改善剂
JP2007051086A (ja) コラーゲンまたはエラスチン代謝異常疾患の予防剤および治療剤
HK1111632B (en) Novel triglyceride reducing agent

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired